Chonluten (20mg Vial) Dosage Protocol

Chonluten (20 mg Vial) Dosage Protocol

Quickstart Highlights

Chonluten dosage protocols focus on this short bioregulatory tripeptide (Glu-Asp-Gly) studied for respiratory health and bronchopulmonary tissue support[1][2]. Research indicates Chonluten may help reduce chronic inflammation, support bronchial epithelium repair, and normalize antioxidant gene expression in lung tissue[3][4]. By modulating pro-inflammatory cytokines like TNF-α and IL-6, Chonluten shows potential to improve airway function and exercise tolerance in respiratory conditions[5]. This educational protocol presents a once-daily subcutaneous approach with gradual titration for research applications.

  • Reconstitute: Add 3.0 mL bacteriostatic water → 6.67 mg/mL concentration.
  • Typical daily range: 250–2000 mcg once daily (gradual titration over 8–12 weeks).
  • Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Chonluten Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 250 mcg 4 units (0.04 mL)
Weeks 3–4 500 mcg 8 units (0.08 mL)
Weeks 5–6 750 mcg 11 units (0.11 mL)
Weeks 7–8 1000 mcg (1 mg) 15 units (0.15 mL)
Weeks 9–10 1500 mcg (1.5 mg) 23 units (0.23 mL)
Weeks 11–12 2000 mcg (2 mg) 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously at a consistent time. For ≤10-unit (≤0.10 mL) administrations during early weeks, consider 30- or 50-unit insulin syringes for improved readability.

Advanced / Extended Approach (Weeks 13–16)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 13–14 3000 mcg (3 mg) 45 units (0.45 mL)
Weeks 15–16 4000 mcg (4 mg) 60 units (0.60 mL)

Advanced dosing (3–4 mg/day) should only be employed if lower doses are well-tolerated. Clear dose-response data in humans are limited; such doses represent the high end of research protocols.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (Chonluten, 20 mg each):

    • 8 weeks ≈ 2 vials (~35 mg total usage)
    • 12 weeks ≈ 5 vials (~84 mg total usage)
    • 16 weeks ≈ 10 vials (~182 mg total usage)
  • Insulin Syringes (U-100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
    • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Chonluten Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support bronchopulmonary tissue repair and reduce chronic inflammation over time[1][3].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks for advanced protocols).
  • Dose Range: 250–2000 mcg daily with gradual titration; up to 4000 mcg in extended protocols.
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 250 mcg daily; increase by ~250–500 mcg every 2 weeks as tolerated.
  • Target: 1000–2000 mcg daily by Weeks 7–12.
  • Advanced: 3000–4000 mcg daily in Weeks 13–16 if lower doses are well-tolerated.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks standard; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality[11][12].

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks[13].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Aliquot and freeze at −20 °C if not using within 4 weeks; avoid repeated freeze–thaw cycles.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[6][7].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • For early-week doses (≤10 units), use 30- or 50-unit syringes for improved accuracy.

How This Works

Chonluten (tripeptide EDG) acts through epigenetic-like mechanisms, binding to DNA/histone regions and altering expression of genes governing cellular stress responses and inflammation[2][3]. In lung tissue models, Chonluten upregulates cytoprotective proteins (c-Fos, HSP70, superoxide dismutase) while modulating inflammatory genes like COX-2 and TNF-α[3]. In immune cell experiments, Chonluten attenuated pro-inflammatory cytokine release (TNF-α, IL-6, IL-17) when challenged with bacterial endotoxin, suggesting it induces a state of TNF tolerance and prevents excessive inflammatory cascades[5]. By dampening NF-κB-driven cytokines while boosting protective stress signals, Chonluten may shift the immune response toward a resolution/healing phenotype[4].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports regeneration of bronchial epithelium and reduction of chronic inflammation markers[1][3].
  • May improve exercise tolerance and overall lung function when used alongside standard therapies in respiratory conditions[4].
  • Downregulates pro-inflammatory cytokines (TNF-α, IL-6) which may help mitigate tissue-damaging inflammation[5].
  • Potential geroprotective effects on respiratory function by normalizing gene expression in aging lung tissue[2].
  • Generally well tolerated in available studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
  • No significant adverse effects reported in the literature, although rigorous clinical trials remain limited.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Avoid smoking and minimize exposure to respiratory irritants to support lung tissue repair.
  • Incorporate regular aerobic exercise to enhance pulmonary function and oxygen utilization.
  • Maintain adequate hydration and a diet rich in antioxidants (vitamins C, E) to complement anti-inflammatory effects.
  • Prioritize sleep and stress management to support immune function and tissue recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[6][7].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8][9].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
  • Rotate sites systematically (abdomen, thighs, upper arms) at least 1–1.5 inches apart to avoid lipohypertrophy[6][7].
  • Dispose of needles immediately in a sharps container; never reuse or recap[10].

Important Note

This content is for educational purposes only and is not medical advice.

References


  • PubMed
    — Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins (Khavinson et al., 2012)
    View Source

  • MDPI Molecules
    — Peptide Regulation of Gene Expression: A Systematic Review (Khavinson et al., 2021)
    View Source

  • MDPI Molecules
    — Peptides: Prospects for Use in the Treatment of COVID-19 (Khavinson et al., 2020)
    View Source

  • ResearchGate (PDF)
    — Peptides: Prospects for Use in the Treatment of COVID-19 (clinical/respiratory applications)
    View Source

  • MDPI IJMS
    — Peptides Regulating Proliferative Activity and Inflammatory Pathways in Monocyte/Macrophage THP-1 Cell Line (Avolio et al., 2022)
    View Source

  • MedlinePlus
    — Subcutaneous (SQ) Injections: Patient Instructions (NIH/NLM)
    View Source

  • Johns Hopkins Arthritis Center
    — How to Give a Subcutaneous Injection (patient education)
    View Source

  • CDC
    — Vaccine Administration: Subcutaneous Route (angle/site; no aspiration)
    View Source

  • CDC (Subcut Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • NCBI Bookshelf
    — Best Practices for Injections (asepsis, preparation, administration)
    View Source

  • Bachem
    — Handling and Storage Guidelines for Peptides (technical guide)
    View Source

  • NIBSC
    — Peptide Handling, Dissolution & Storage (UK MHRA resource)
    View Source

  • Creative Peptides
    — Peptide Stability & Shelf Life: How Long Do Peptides Last? (technical article)
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Pharmacologic considerations of the subcutaneous route
    View Source

  • Pure Lab Peptides
    — Chonluten (20 mg) product page (quality and batch documentation)
    View Source